William G. Wierda

Statistics

Publications

532

Citations

55.9K

H-Index

117

Active since

1989

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

University of California San Diego

University of California, Irvine

The Ohio State University

William G. Wierda is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematologic malignancy therapy.

ORCID

Publications per year

1989–2025

532

Publications

532

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text

Medicine, Hematology, Oncology +12

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu, David Marín, Pinaki P. Banerjee et al. · New England Journal of Medicine · 2020 · 2.1K citations · Full text

Life Sciences, Immunology, Oncology +17

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text

Medicine, Cancer Biology, Oncology +14

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Bonnie K. Harrington, Susan O’Brien et al. · New England Journal of Medicine · 2015 · 891 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W. Roberts, John F. Seymour, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2011 · 818 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

1–5 of 532